REGN Financial Facts

Selling, general, and administrative: 270.05M
Cost of goods sold: 29.9M
See Full Income Statement

Total liabilities and stockholders' equity: 6.83B
Total assets: 6.83B
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/30/-1 Q112 $0.00-$0.24 +$0.24N/A$172.62M N/A Details
11/4/16 Q316 $3.13$2.73 +$0.40$1.22B$1.29B N/A Details
7/25/12 Q212 $0.90$0.25 +$0.65$304M$255.98M N/A Details
11/5/19 Q319 $6.67$6.36 +$0.31$2.05B$1.99B N/A Details
2/6/20 Q419 $7.50$6.92 +$0.58$2.17B$2.11B N/A Details
2/9/17 Q416 $3.04$3.03 +$0.01$1.23B$1.3B = Details
2/11/14 Q413 $2.24$0.97 +$1.27$610M$579.17M N/A Details
5/5/20 Q120 $6.60$6.13 +$0.47$1.83B$1.76B N/A Details